A Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial Spondyloarthritis

Phase 3

Recruiting

• Conditions: Active Non-radiographic Axial Spondyloarthritis
• Interventions: Drug: SHR-1314 Injection; Drug: SHR-1314 Placebo Injection

• Registration Number: NCT06860750
• Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Brief Summary

The study is being conducted to evaluate the efficacy and safety of SHR-1314 injection in adult patients with active non-radiographic axial spondyloarthritis.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-03-02
• Study First Submitted QC: 2025-03-02
• Study First Posted: 2025-03-06
• Study Start: 2025-04-29
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-07
• Last Update Posted: 2025-05-08
• Primary Completion: 2027-04
• Study Completion: 2028-02

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 380

Inclusion Criteria

1. Age ≥ 18 years at the time of signing the informed consent form, regardless of gender.
2. BMI (Body Mass Index) ≥ 18 kg/m² at the time of screening.
3. Presence of objective signs of inflammation at the time of screening.
4. The subject voluntarily signs the ICF (informed consent form) before the start of any study-related procedures.
5. The subject is able to communicate effectively with the investigator, understands and is willing to strictly adhere to the requirements of the clinical study protocol to complete the study.

Exclusion Criteria

1. Subjects with active systemic infection or severe infection.
2. Subjects with active tuberculosis or latent tuberculosis infection.
3. Subjects with lymphoma or lymphoproliferative disease.
4. Subjects with uncontrolled hypertension.
5. Subjects with history of malignancy within the past 5 years or current malignancy.
6. Subjects with moderate to severe congestive heart failure.
7. Subjects with history of organ transplantation, or severe, progressive, or uncontrolled diseases of any organ system.
8. Presence of protocol-defined abnormalities in laboratory tests and/or 12-lead ECG at the time of screening.
9. Pregnant or breastfeeding women.
10. known allergy to the study drug or any of its components.
11. Subjects with history of alcohol abuse or illegal drug use within the past year.
12. Receipt of a live vaccine within 12 weeks before randomization, or plans to receive a live vaccine during the study period.
13. Blood donation of approximately 500 mL within 8 weeks before randomization, or plans to donate blood during the study period.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
SHR-1314 Injection	SHR-1314 Injection	Subjects will receive SHR-1314 injection in the core treatment period and the extended treatment period.
SHR-1314 Placebo Injection	SHR-1314 Injection	Subjects will receive SHR-1314 placebo injection in the core treatment period and receive SHR-1314 injection in the extended treatment period.
SHR-1314 Placebo Injection	SHR-1314 Placebo Injection	Subjects will receive SHR-1314 placebo injection in the core treatment period and receive SHR-1314 injection in the extended treatment period.

Primary Outcome Measures

Name	Time	Method
Proportion of participants achieving ASAS 40 (ankylosing spondylitis disease activity score).	At the 16th week after administration.

Secondary Outcome Measures

Name	Time	Method
Proportion of participants achieving ASAS 20 (ankylosing spondylitis disease activity score).	At the 16th week after administration.
Change in CRP (C-reactive protein) value from baseline.	At the 16th week after administration.
AEs (adverse events).	Up to 60 weeks after administration.

Trial Locations

Locations (1)

Chinese PLA General Hospital; 🇨🇳 Beijing, Beijing, China